Overview

Effects of Vildagliptine and Glimepiride on Glucose Variability

Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to analyze the differences of blood sugar level and glycemic variability between sulfonylurea and DPP-4 inhibitor groups applying CGMS for a chosen number of type 2 DM patients. The investigators also reveal influences of each drugs on cardiovascular risk factors by measuring related biomarkers.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Seoul National University Hospital
Treatments:
Glimepiride
Vildagliptin
Criteria
Inclusion Criteria:

- with type 2 DM

- with uncontrolled glucose level on Metformin monotherapy over 1000mg /day (HbA1C over
7%). Provided that the tolerance for metformin is poor, enrollment of patients with
lower dose of metfomrin is open.

- who have never been prescribed with test drugs, sulfonylurea or DPP-4 inhibitor/GLP-1
analogue in 3 months

- who can be applied with CGMS

Exclusion Criteria:

- who has liver function abnormality or renal function abnormality

- who has any kind of diseases, operations, medical treatments that can affect glucose
levels